Old and novel therapies for primary biliary cirrhosis

Seminars in Liver Disease

Volumn 34, Issue 3, 2014, Pages 341-351

  Parés, Albert ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

bisphosphonates; budesonide; fibrates; obeticholic acid; osteoporosis; pruritus; ursodeoxycholic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CYCLOSPORIN A; FIBRIC ACID DERIVATIVE; IBANDRONIC ACID; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; METHOTREXATE; NALTREXONE; OBETICHOLIC ACID; PLACEBO; RESIN; RIFAMPICIN; RITUXIMAB; SERTRALINE; URSODEOXYCHOLIC ACID; ZIDOVUDINE; ANTIINFLAMMATORY AGENT; ANTIPRURITIC AGENT; BONE DENSITY CONSERVATION AGENT; CHOLAGOGUE; GASTROINTESTINAL AGENT;

ALBUMIN DIALYSIS; ARTICLE; BONE MASS; CHOLESTASIS; CLINICAL TRIAL; DIET SUPPLEMENTATION; ESOPHAGITIS; FATIGUE; HEARTBURN; HUMAN; INVASIVE PROCEDURE; LONG TERM CARE; MOLECULAR THERAPY; OSTEOPOROSIS; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PRURITUS; SURVIVAL; VITAMIN SUPPLEMENTATION; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; IMMUNOLOGY; INTRAHEPATIC BILE DUCT; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; PATHOLOGY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIPRURITICS; BILE DUCTS, INTRAHEPATIC; BONE DENSITY CONSERVATION AGENTS; CHOLAGOGUES AND CHOLERETICS; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; OSTEOPOROSIS; PRURITUS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84905048563     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1383733     Document Type: Article

References (141)

1. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol: 2009; 51 2 237 267
2. Lindor K. D., Gershwin M. E., Poupon R., Kaplan M., Bergasa N. V., Heathcote E. J. American Association for Study of Liver Diseases Primary biliary cirrhosis. Hepatology: 2009; 50 1 291 308
3. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol: 2006; 3 6 318 328
4. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol: 2012; 36 01 S3 S12
5. Poupon R., Chrétien Y., Poupon R. E., Ballet F., Calmus Y., Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet: 1987; 1 8537 834 836
6. Poupon R. E., Balkau B., Eschwège E., Poupon R. UDCA-PBC Study Group A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med: 1991; 324 22 1548 1554
7. Heathcote E. J., Cauch-Dudek K., Walker V., et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology: 1994; 19 5 1149 1156
8. Lindor K. D., Dickson E. R., Baldus W. P., et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology: 1994; 106 5 1284 1290
9. Combes B., Carithers R. L. Jr, Maddrey W. C., et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology: 1995; 22 3 759 766
10. Parés A., Caballería L., Rodés J., et al. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol: 2000; 32 4 561 566
11. Poupon R. E., Lindor K. D., Parés A., Chazouillères O., Poupon R., Heathcote E. J. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol: 2003; 39 1 12 16
12. Poupon R. E., Lindor K. D., Cauch-Dudek K., Dickson E. R., Poupon R., Heathcote E. J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology: 1997; 113 3 884 890
13. Goulis J., Leandro G., Burroughs A. K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet: 1999; 354 9184 1053 1060
14. Gong Y., Huang Z., Christensen E., Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol: 2007; 102 8 1799 1807
15. Rudic J. S., Poropat G., Krstic M. N., Bjelakovic G., Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev: 2012; 12 CD000551 10.1002/14651858.CD000551
16. Shi J., Wu C., Lin Y., Chen Y. X., Zhu L., Xie W. F. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol: 2006; 101 7 1529 1538
17. Angulo P., Dickson E. R., Therneau T. M., et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol: 1999; 30 5 830 835
18. Parés A., Caballería L., Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology: 2006; 130 3 715 720
19. Corpechot C., Abenavoli L., Rabahi N., et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology: 2008; 48 3 871 877
20. Kuiper E. M., Hansen B. E., de Vries R. A., et al. Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology: 2009; 136 4 1281 1287
21. Kumagi T., Guindi M., Fischer S. E., et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol: 2010; 105 10 2186 2194
22. Corpechot C., Chazouillères O., Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol: 2011; 55 6 1361 1367
23. Zhang L. N., Shi T. Y., Shi X. H., et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology: 2013; 58 1 264 272
24. Cavazza A., Caballería L., Floreani A., et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology: 2009; 50 4 1162 1168
25. Kuiper E. M., Hansen B. E., Adang R. P., et al. Dutch PBC Study Group. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol: 2010; 22 12 1495 1502
26. Jackson H., Solaymani-Dodaran M., Card T. R., Aithal G. P., Logan R., West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology: 2007; 46 4 1131 1137
27. Nakai S., Masaki T., Kurokohchi K., Deguchi A., Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol: 2000; 95 1 326 327
28. Kurihara T., Niimi A., Maeda A., Shigemoto M., Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol: 2000; 95 10 2990 2992
29. Ohira H., Sato Y., Ueno T., Sata M. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol: 2002; 97 8 2147 2149
30. Kanda T., Yokosuka O., Imazeki F., Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol: 2003; 38 6 573 578
31. Akbar S. M., Furukawa S., Nakanishi S., Abe M., Horiike N., Onji M. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J Gastroenterol: 2005; 40 2 157 163
32. Kita R., Takamatsu S., Kimura T., Kokuryu H., Osaki Y., Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol: 2006; 41 7 686 692
33. Walker L. J., Newton J., Jones D. E., Bassendine M. F. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology: 2009; 49 1 337 338, author reply 338
34. Hazzan R., Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol: 2010; 44 5 371 373
35. Liberopoulos E. N., Florentin M., Elisaf M. S., Mikhailidis D. P., Tsianos E. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J: 2010; 4 120 126
36. Levy C., Peter J. A., Nelson D. R., et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther: 2011; 33 2 235 242
37. Lens S., Leoz M., Nazal L., Bruguera M., Parés A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int: 2014; 34 2 197 203
38. Honda A., Ikegami T., Nakamuta M., et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology: 2013; 57 5 1931 1941
39. Matsumoto T., Miyazaki H., Nakahashi Y., et al. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res: 2004; 30 3 125 136
40. Chianale J., Vollrath V., Wielandt A. M., et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J: 1996; 314 Pt 3 781 786
41. Leuschner M., Maier K. P., Schlichting J., et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology: 1999; 117 4 918 925
42. Rautiainen H., Kärkkäinen P., Karvonen A. L., et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology: 2005; 41 4 747 752
43. Angulo P., Jorgensen R. A., Keach J. C., Dickson E. R., Smith C., Lindor K. D. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology: 2000; 31 2 318 323
44. Hempfling W., Grunhage F., Dilger K., Reichel C., Beuers U., Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology: 2003; 38 1 196 202
45. Pellicciari R., Fiorucci S., Camaioni E., et al. 6alpha-ethyl- chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem: 2002; 45 17 3569 3572
46. Fiorucci S., Rizzo G., Donini A., Distrutti E., Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med: 2007; 13 7 298 309
47. Pellicciari R., Costantino G., Fiorucci S. Farnesoid X receptor: from structure to potential clinical applications. J Med Chem: 2005; 48 17 5383 5403
48. Trauner M., Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology: 2011; 140 4 1120 1125, e1-e12
49. Fiorucci S., Antonelli E., Rizzo G., et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology: 2004; 127 5 1497 1512
50. Fiorucci S., Rizzo G., Antonelli E., et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther: 2005; 315 1 58 68
51. Mason A., Luketic V. A., Lindor K. D., et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of obeticholic acid (int-747) to ursodeoxycholic acid (Abstract). Hepatology: 2010; 52 375A
52. Marschall H. U., Luketic V., Lövgren-Sandblom A., et al. The farnesoid X receptor (FXR) agonist obeticholic acid (OCA) increases plasma FGF- 19 concen- trations and decreases bile acid synthesis in primary biliary cirrhosis (PBC) (Abstract). J Hepatol: 2012; 56 (Suppl 2): S377
53. Kowdley K. V., Jones D., Luketic V., et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC (Abstract). J Hepatol: 2011; 54 S13
54. Myers R. P., Swain M. G., Lee S. S., Shaheen A. AM, Burak K. W. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol: 2013; 108 6 933 941
55. Hirschfield G. M., Liu X., Xu C., et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med: 2009; 360 24 2544 2555
56. Xu L., Shen Z., Guo L., et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A: 2003; 100 14 8454 8459
57. Mason A. L., Farr G. H., Xu L., Hubscher S. G., Neuberger J. M. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol: 2004; 99 12 2348 2355
58. Mason A. L., Lindor K. D., Bacon B. R., et al. Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther: 2008; 28 7 886 894
59. Hendrickse M. T., Rigney E., Giaffer M. H., et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology: 1999; 117 2 400 407
60. González-Koch A., Brahm J., Antezana C., Smok G., Cumsille M. A. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol: 1997; 27 1 143 149
61. Combes B., Emerson S. S., Flye N. L., et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology: 2005; 42 5 1184 1193
62. Kaplan M. M., Bonder A., Ruthazer R., Bonis P. A. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci: 2010; 55 11 3207 3217
63. Giljaca V., Poropat G., Stimac D., Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev: 2010; 5 CD004385
64. Bodenheimer H. Jr, Schaffner F., Pezzullo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology: 1988; 95 1 124 129
65. Kaplan M. M., Alling D. W., Zimmerman H. J., et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med: 1986; 315 23 1448 1454
66. Vuoristo M., Färkkilä M., Karvonen A. L., et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology: 1995; 108 5 1470 1478
67. Warnes T. W., Smith A., Lee F. I., Haboubi N. Y., Johnson P. J., Hunt L. A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. J Hepatol: 1987; 5 1 1 7
68. Zifroni A., Schaffner F. Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy. Hepatology: 1991; 14 6 990 993
69. Poupon R. E., Huet P. M., Poupon R., Bonnand A. M., Nhieu J. T., Zafrani E. S. UDCA-PBC Study Group A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. Hepatology: 1996; 24 5 1098 1103
70. Gong Y., Gluud C. Colchicine for primary biliary cirrhosis: a Cochrane Hepato-Biliary Group systematic review of randomized clinical trials. Am J Gastroenterol: 2005; 100 8 1876 1885
71. Wiesner R. H., Ludwig J., Lindor K. D., et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med: 1990; 322 20 1419 1424
72. Lombard M., Portmann B., Neuberger J., et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology: 1993; 104 2 519 526
73. Guañabens N., Parés A., Navasa M., et al. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. J Hepatol: 1994; 21 1 24 28
74. Hoofnagle J. H., Davis G. L., Schafer D. F., et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology: 1986; 91 6 1327 1334
75. Angulo P., Patel T., Jorgensen R. A., Therneau T. M., Lindor K. D. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology: 2000; 32 5 897 900
76. The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. J Hepatol: 1993; 17 2 227 235
77. McCormick P. A., Scott F., Epstein O., Burroughs A. K., Scheuer P. J., McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J Hepatol: 1994; 21 4 496 499
78. Jones E. A., ten Kate F. J., ter Borg F., Houben M., Reesink H. W., Chamuleau R. A. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol: 1999; 11 10 1165 1169
79. Leuschner M., Holtmeier J., Ackermann H., Leuschner U. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study. Eur J Gastroenterol Hepatol: 2002; 14 12 1369 1376
80. Stojakovic T., Putz-Bankuti C., Fauler G., et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology: 2007; 46 3 776 784
81. Cash W. J., O'Neill S., O'Donnell M. E., et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int: 2013; 33 8 1166 1174
82. Invernizzi P., Alvaro D., Crosignani A., Gaudio E., Podda M. Tamoxifen in treatment of primary biliary cirrhosis. Hepatology: 2004; 39 4 1175 1176
83. Phillips J. R., Angulo P., Petterson T., Lindor K. D. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol: 2001; 96 9 2745 2750
84. Pares A., Caballeria L., Deulofeu R., Rodés J. Circulating fat-soluble vitamins and antioxidants in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology: 2005; 42 4 470A
85. Kaplan M. M., Elta G. H., Furie B., Sadowski J. A., Russell R. M. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology: 1988; 95 3 787 792
86. Matloff D. S., Kaplan M. M., Neer R. M., Goldberg M. J., Bitman W., Wolfe H. J. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology: 1982; 83 1 Pt 1 97 102
87. Sokol R. J., Kim Y. S., Hoofnagle J. H., Heubi J. E., Jones E. A., Balistreri W. F. Intestinal malabsorption of vitamin E in primary biliary cirrhosis. Gastroenterology: 1989; 96 2 Pt 1 479 486
88. Carey J. B. Jr, Williams G. Relief of the pruritus of jaundice with a bile-acid sequestering resin. JAMA: 1961; 176 432 435
89. Garbutt J. T., Kenney T. J. Effect of cholestyramine on bile acid metabolism in normal man. J Clin Invest: 1972; 51 11 2781 2789
90. Javitt N. B. Timing of cholestyramine doses in cholestatic liver disease. N Engl J Med: 1974; 290 23 1328 1329
91. Rust C., Sauter G. H., Oswald M., et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest: 2000; 30 2 135 139
92. Kuiper E. M., van Erpecum K. J., Beuers U., et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology: 2010; 52 4 1334 1340
93. Ghent C. N., Carruthers S. G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology: 1988; 94 2 488 493
94. Bachs L., Parés A., Elena M., Piera C., Rodés J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet: 1989; 1 8638 574 576
95. Podesta A., Lopez P., Terg R., et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci: 1991; 36 2 216 220
96. Bachs L., Parés A., Elena M., Piera C., Rodés J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology: 1992; 102 6 2077 2080
97. Prince M. I., Burt A. D., Jones D. EJ. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut: 2002; 50 3 436 439
98. Tandon P., Rowe B. H., Vandermeer B., Bain V. G. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol: 2007; 102 7 1528 1536
99. Khurana S., Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int: 2006; 26 8 943 948
100. Bloomer J. R., Boyer J. L. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med: 1975; 82 3 310 317
101. Wolfhagen F. HJ, Sternieri E., Hop W. CJ, Vitale G., Bertolotti M., Van Buuren H. R. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology: 1997; 113 4 1264 1269
102. Terg R., Coronel E., Sordá J., Muñoz A. E., Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol: 2002; 37 6 717 722
103. Bergasa N. V., Schmitt J. M., Talbot T. L., et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology: 1998; 27 3 679 684
104. Bergasa N. V., Talbot T. L., Alling D. W., et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology: 1992; 102 2 544 549
105. Browning J., Combes B., Mayo M. J. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol: 2003; 98 12 2736 2741
106. Mayo M. J., Handem I., Saldana S., Jacobe H., Getachew Y., Rush A. J. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology: 2007; 45 3 666 674
107. Borgeat A., Wilder-Smith O. H., Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology: 1993; 104 1 244 247
108. Frezza M., Centini G., Cammareri G., Le Grazie C., Di Padova C. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepatogastroenterology: 1990; 37 02 122 125
109. Cerio R., Murphy G. M., Sladen G. E., MacDonald D. M. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br J Dermatol: 1987; 116 2 265 267
110. Cohen L. B., Ambinder E. P., Wolke A. M., Field S. P., Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut: 1985; 26 3 291 294
111. Quintero E., Puig L., Parés A., et al. Utilidad del recambio plasmático intermitente en la cirrosis biliar primaria. Gastroenterol Hepatol: 1986; 9 7 329 333
112. Alallam A., Barth D., Heathcote E. J. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol: 2008; 22 5 505 507
113. Pusl T., Denk G. U., Parhofer K. G., Beuers U. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol: 2006; 45 6 887 891
114. Macia M., Avilés J., Navarro J., Morales S., García J. Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. Am J Med: 2003; 114 1 62 64
115. Doria C., Mandalá L., Smith J., et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl: 2003; 9 4 437 443
116. Parés A., Cisneros L., Salmerón J. M., et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol: 2004; 99 6 1105 1110
117. Parés A., Herrera M., Avilés J., Sanz M., Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol: 2010; 53 2 307 312
118. Kremer A. E., van Dijk R., Leckie P., et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology: 2012; 56 4 1391 1400
119. Beuers U., Gerken G., Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology: 2006; 44 1 280 281
120. Newton J. L., Pairman J., Sutcliffe K., Wilton K., Jones D. EJ. A predictive model for fatigue and its etiologic associations in primary biliary cirrhosis. Clin Gastroenterol Hepatol: 2008; 6 2 228 233
121. Newton J. L., Gibson G. J., Tomlinson M., Wilton K., Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology: 2006; 44 1 91 98
122. Kaplan M. M., Bonis P. A. Modafinil for the treatment of fatigue in primary biliary cirrhosis. Ann Intern Med: 2005; 143 7 546 547
123. Ian Gan S., de Jongh M., Kaplan M. M. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci: 2009; 54 10 2242 2246
124. Jones D. E., Newton J. L. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther: 2007; 25 4 471 476
125. Parés A., Guañabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis: 2008; 12 2 407 424
126. Ruiz-Gaspà S., Guañabens N., Enjuanes A., et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest: 2010; 40 1 25 34
127. Ruiz-Gaspà S., Martinez-Ferrer A., Guañabens N., et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology: 2011; 54 6 2104 2113
128. Dubreuil M., Ruiz-Gaspà S., Guañabens N., et al. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. Liver Int: 2013; 33 7 1029 1038
129. Guañabens N., Cerdá D., Monegal A., et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology: 2010; 138 7 2348 2356
130. Guañabens N., Parés A., Monegal A., et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology: 1997; 113 1 219 224
131. Guañabens N., Parés A., Ros I., et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol: 2003; 98 10 2268 2274
132. Wolfhagen F. HJ, van Buuren H. R., den Ouden J. W., et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol: 1997; 26 2 325 330
133. Musialik J., Petelenz M., Gonciarz Z. Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year. Scand J Gastroenterol: 2005; 40 7 873 874
134. Zein C. O., Jorgensen R. A., Clarke B., et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology: 2005; 42 4 762 771
135. Guañabens N., Monegal A., Cerdá D., et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology: 2013; 58 6 2070 2078
136. Cryer B., Bauer D. C. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc: 2002; 77 10 1031 1043
137. Treeprasertsuk S., Silveira M. G., Petz J. L., Lindor K. D. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther: 2011; 18 5 375 381
138. Lee J., Belanger A., Doucette J. T., Stanca C., Friedman S., Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol: 2007; 5 11 1313 1315
139. Markus B. H., Dickson E. R., Grambsch P. M., et al. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med: 1989; 320 26 1709 1713
140. Klion F. M., Fabry T. L., Palmer M., Schaffner F. Prediction of survival of patients with primary biliary cirrhosis. Examination of the Mayo Clinic model on a group of patients with known endpoint. Gastroenterology: 1992; 102 1 310 313
141. Milkiewicz P. Liver transplantation in primary biliary cirrhosis. Clin Liver Dis: 2008; 12 2 461 472, xi